COMPARATIVE VACCINE HESITANCY IN PEOPLE WITH COPD

Abstract

TOPIC: Obstructive Lung Diseases TYPE: Original Investigations PURPOSE: To understand comparative vaccine (influenza, “pneumonia” and shingles) use and reasons for hesitancy among people with COPD known to be at increased risk for poor outcomes from vaccine preventable diseases.To understand the potential impact of a short educational video (the intervention) on self-reported shingles vaccine uptake intent and interest. METHODS: An intervention study conducted in members of the COPD Foundation’s Patient Powered Research Network (PPRN). All had self-reported COPD. A survey queried about receipt of influenza, shingles and “pneumonia” vaccines and reasons for not receiving those vaccines. For individuals not receiving the newest of those vaccines (shingles), a 5-minute educational video was presented discussing general shingles disease burden and increased risk in those with COPD, and disease prevention from vaccination. A 1-minute patient (COPD + shingles) testimonial was included in the video. After viewing, participants were asked about the value and potential impact of the video. RESULTS: 735 people responded; 60% women, mean age 68.5 years, 53% reporting poor overall health and 54% having >1 exacerbations in past 12 months. Vaccination rates were 93% for pneumonia vaccines, 89% for influenza vaccines and 61% for shingles vaccines. Health care recommendations varied by site: highest in primary care (61 to 91%) and from internet or family and friends (35 to 47%) and lower rates of recommendations by pulmonologists (21 to 61%) and pharmacies (30 to 53%) among those attending the specific site. The most common reasons for not receiving a vaccine were lack of health care professional recommendation (7% for influenza to >30% for pneumonia and shingles), concerns about side effects (pneumonia 22%, shingles 38% and influenza 43%), inadequate information (influenza 11%, pneumonia 20%, shingles 32%) and for influenza and shingles vaccines—fear of vaccine causing the disease (28% and 22% respectively). Only 25% were aware that COPD increased the risk of developing shingles. The video was felt to be useful (>94%) and increased interest and intent for receiving the shingles vaccine or at least discussing receipt with their physician (>87%). Awareness of increased risk of shingles in those with COPD increased to 91%. CONCLUSIONS: Vaccine hesitancy continues among those living with COPD, particularly for newer vaccines such as shingles.Health care professionals’ recommendations are not universal.A short educational intervention may lower vaccine hesitancy and may have implications for addressing COVID vaccine acceptance. CLINICAL IMPLICATIONS: Care of people with COPD must include clear vaccine recommendations and information about preventable disease burden, vaccine effectiveness and accurate side effect profiles from all the Health Care Professionals they visit. DISCLOSURES: Received funding from GSK relationship with GlaxoSmithKline Please note: 04/01/20-12/31/21 Added 04/30/2021 by Elisabeth Callen, source=Web Response, value=Grant/Research Support No relevant relationships by Janice Cotton, source=Web Response No relevant relationships by Natalia Loskutova, source=Web Response No relevant relationships by Sergio Martinez, source=Web Response No relevant relationships by Debora Merrill, source=Web Response No relevant relationships by Dennis Williams, source=Web Response Consultant relationship with GSK Please note: $5001 - $20000 by Barbara Yawn, source=Web Response, value=Consulting fee Advisory Committee Member relationship with BI Please note: $1001 - $5000 by Barbara Yawn, source=Web Response, value=Honoraria Advisory Committee Member relationship with AZ Please note: $1001 - $5000 by Barbara Yawn, source=Web Response, value=Honoraria Advisory Committee Member relationship with Sunovian Please note: $1001 - $5000 by Barbara Yawn, source=Web Response, value=Honoraria Removed 02/15/2021 by Barbara Yawn, source=Web Response Advisory Committee Member relationship with TEVA Please note: 11/2019-12/2021 Added 02/15/2021 by Barbara Yawn, source=Web Response, value=Consulting fee